PRIMO 2024 | Groundbreaking research in gliomas: insights from the INDIGO trial

Glenn Lesser, MD, Wake Forest School of Medicine, Winston-Salem, NC, discusses groundbreaking research in gliomas, highlighting the Phase III INDIGO trial (NCT04164901), the first large-scale study examining the role of the IDH inhibitor vorasidenib in IDH mutant low-grade gliomas. IDH inhibitors, previously used in other cancers, have shown promise in targeting the specific mutations present in gliomas. The trial demonstrated a significant improvement in progression-free survival (PFS) and time to next intervention for patients treated with an IDH inhibitor compared to those on observation or placebo. Dr Lesser anticipates regulatory approval for the IDH inhibitor based on the positive trial results. He emphasizes the importance of this development in a field where treatment advances have been limited, particularly given the significant impact of gliomas on affected patients’ lives. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.